Drug intelligence / Profile preview

Xingqinganke

Development stage: Unknown
Lead developer: Shuguang Hospital
Modality: Small Molecules
Administration: Oral

Overview

Xingqinganke is a Traditional Chinese Medicine (TCM) granule currently undergoing a randomized controlled phase II clinical trial for the treatment of post-cold cough. Developed by Shijiazhuang Oriental Pharmaceutical Co., LTD and Shuguang Hospital Affiliated to Shanghai University of T.C.M., this oral formulation is expected to contain multiple herbal components, characteristic of TCM granules, which are believed to act synergistically to alleviate cough symptoms. Specific active ingredients and detailed molecular mechanisms are not publicly available.

Beyond the preview

Go deeper on Xingqinganke.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xingqinganke.

Explore the full profile